DZD9008 for Non-Small Cell Lung Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Non-Small Cell Lung Cancer+1 MoreDZD9008 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test a new drug on patients with advanced lung cancer who have progressed after other treatments. It will help to understand side effects and how well the drug works on its own.

Eligible Conditions
  • Non-Small Cell Lung Cancer

Treatment Effectiveness

Study Objectives

2 Primary · 1 Secondary · Reporting Duration: through the study completion, an average of around 1 year

Day 28
Part A: Safety and tolerability of DZD9008.
Day 28
Plasma DZD9008 concentration
Year 1
Part B: Objective Response Rate (ORR) according to RECIST 1.1.

Trial Safety

Trial Design

9 Treatment Groups

DZD9008
1 of 9
Part A Dose expansion cohort 4 (Ongoing)
1 of 9
Part A Dose expansion cohort 5 (Ongoing)
1 of 9
Part A Dose expansion cohort 3
1 of 9
Part A Dose expansion cohort 2
1 of 9
Part A Dose expansion cohort 6
1 of 9
Part A Dose escalation
1 of 9
Part A Dose expansion cohort 1
1 of 9
Part B Dose extension (Ongoing)
1 of 9

Experimental Treatment

336 Total Participants · 9 Treatment Groups

Primary Treatment: DZD9008 · No Placebo Group · Phase 1 & 2

DZD9008
Drug
Experimental Group · 1 Intervention: DZD9008 · Intervention Types: Drug
Part A Dose expansion cohort 4 (Ongoing)
Drug
Experimental Group · 1 Intervention: DZD9008 · Intervention Types: Drug
Part A Dose expansion cohort 5 (Ongoing)
Drug
Experimental Group · 1 Intervention: DZD9008 · Intervention Types: Drug
Part A Dose expansion cohort 3
Drug
Experimental Group · 1 Intervention: DZD9008 · Intervention Types: Drug
Part A Dose expansion cohort 2
Drug
Experimental Group · 1 Intervention: DZD9008 · Intervention Types: Drug
Part A Dose expansion cohort 6
Drug
Experimental Group · 1 Intervention: DZD9008 · Intervention Types: Drug
Part A Dose escalation
Drug
Experimental Group · 1 Intervention: DZD9008 · Intervention Types: Drug
Part A Dose expansion cohort 1
Drug
Experimental Group · 1 Intervention: DZD9008 · Intervention Types: Drug
Part B Dose extension (Ongoing)
Drug
Experimental Group · 1 Intervention: DZD9008 · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
DZD9008
2021
Completed Phase 1
~80

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through the study completion, an average of around 1 year

Who is running the clinical trial?

Dizal PharmaceuticalsLead Sponsor
13 Previous Clinical Trials
953 Total Patients Enrolled
Pasi Antero Janne, M.D & Ph. DPrincipal InvestigatorDana-Farber Cancer Institute

Eligibility Criteria

Age 18+ · All Participants · 12 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Who else is applying?

What state do they live in?
Ohio33.3%
Michigan11.1%
Indiana11.1%
Other44.4%
What site did they apply to?
H. Lee Moffitt Cancer Center & Research Institute25.0%
The Ohio State University Comprehensive Cancer Center50.0%
Michigan Center of Medical Research25.0%
What portion of applicants met pre-screening criteria?
Met criteria66.7%
Did not meet criteria33.3%
Why did patients apply to this trial?
  • "MY Doctor has indicated my SPA is elevated. Right now that's all I know"
  • "My 1 year older brother just died in December 2022 after they found mini cancer fells in his lungs plus then finding hundreds of mini cancer cells in his brain. They gave him 1-2 years to livr but he died 2 weeks later"
How many prior treatments have patients received?
066.7%
133.3%